Alladapt's 15-allergen drug desensitizes kids to multiple foods, teeing up pivotal program

Alladapt Immunotherapeutics has delivered early clinical evidence that it can desensitize multiple food allergies with a single oral immunotherapy. The phase 1/2 clinical trial reported dose-dependent changes in recipients of the multi-allergen candidate, encouraging the company to plot a late-stage program.